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1. Introduction
Atrial fibrillation is the most common sustained cardiac arrhythmia, which is associated
with a high risk of stroke and thromboembolism. Increasing evidence suggests that the
thrombogenic tendency in atrial fibrillation is related to several underlying pathophysiologi‐
cal mechanisms. Virchow’s triad, a time-honored paradigm that offers mechanistic insights
for thrombus initiation and development regardless of origin, does indeed apply to atrial fi‐
brillation thrombogenesis [1,2].
2. Mechanisms of thrombogenesis in atrial fibrillation
More than 150 years ago, Rudolf Virchow proposed a triad of events needed for thrombus
formation ie, abnormal changes of the vessel wall, blood flow, and blood constituents [2]. In
the 21st century, we now recognize Virchow’s triad as: endothelial or endocardial damage
or dysfunction (and related structural abnormal changes); abnormal blood stasis; and abnor‐
mal haemostasis, platelets, and fibrinolysis (Figure 1). Extensive abnormal changes of these
variables are clearly evident in atrial fibrillation. Thus, atrial fibrillation could in fact drive a
prothrombotic or hypercoagulable state, by virtue of its fulfillment of Virchow’s triad for
thrombogenesis [3].
Abnormal changes shown in the vessel wall (eg, atrial tissue changes, endothelial damage
and dysfunction), in fl ow (stasis—eg, in the left atrial appendage), and in blood constituents
(eg, haemoconcentration, platelets, coagulation cascade activation, infl ammation); all fac‐
tors contribute to propensity for thrombus formation (thrombogenesis) in atrial fi brillation.
vWf=von Willebrand factor.
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Figure 1. Components of Virchow’s triad for thrombogenesis in atrial fibrillation [4](with permission)
2.1. Anatomical and structural considerations:
Attached to each atria is a blind-ended passage known as an appendage. The left atrial ap‐
pendage (LAA) is long with a narrow inlet, thereby predisposing to blood stasis. Thus, the
LAA is the most common site of intra-atrial thrombus formation, not only in atrial fibrilla‐
tion, but also in patients with sinus rhythm [5,6].
Changes in the dimensions of the left atrium and LAA occur as a consequence of atrial fibril‐
lation, with some correlation to subsequent thromboembolism. Detailed descriptions of en‐
dothelial damage in the context of atrial fibrillation are well described and can be visualised
by scanning electron microscopy, especially within the appendages. Goldsmith and collea‐
gues [7] have reported more severe endocardial changes in the LAA than in the right-atrial
appendages, especially in atrial fibrillation (compared with sinus rhythm) and in mitral
stenosis (compared with mitral regurgitation). Similarly, Masawa and co-workers [8] have
described a “rough endocardium” with a wrinkled appearance attributable to oedema and
fibrinous transformation; small areas of endothelial denudation and thrombotic aggregation
have also been noted in patients with atrial fibrillation and cerebral embolism.
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Extracellular matrix turnover is a dynamic structure, which continually undergoes a process
of structural remodeling [9]. Structural remodelling of the atria could contribute to the hy‐
percoagulable state, by virtue of both enhanced blood stasis and an abnormal endocardium.
Structural remodeling of the left atrial appendage to include the pectinate muscles and mul‐
tiple lobes of the lumen occurs in patients with permanent atrial fibrillation [10]. Morpho‐
logic studies have shown larger volumes and luminal surface areas when compared to
patients without atrial fibrillation; however, both the absolute and relative surface areas of
the pectinate muscles are reduced. In addition, there is significant endocardial thickening
with fibrous and elastic tissue (endocardialfibroelastosis) [10].
Several studies have shown that patients with atrial fibrillation have altered amounts of col‐
lagen degradation products and impaired matrix degradation, with abnormal plasma con‐
centrations of various matrix metalloproteinases (MMPs), their inhibitors (tissue inhibitor of
MMPs [TIMPs]), and various growth factors (eg, transforming growth factor β1) reported
[11-13]. These proteins are important in the breakdown of various collagens and hence their
regulation is key to ensuring healthy matrix turnover.
Evidence suggests that abnormal changes in the extracellular matrix are not related to the
presence of atrial fibrillation in itself, but are probably a consequence of various coexisting
comorbidities (eg, hypertension). Nevertheless, MMPs and TIMPs could have a link with the
prothrombotic state, as exemplified by a correlation with prothrombin fragments 1 and 2,
markers of thrombogenesis [12]. Further studies have identified disruption of other extracel‐
lular matrix components, although most have focused on these factors as a cause for the ar‐
rhythmia or explanation for remodelling and chamber dilatation [14-17]. One study
suggested that some of the changes in MMPs were due to concomitant mitral valve disease
[16], whereas another reported changes in the ventricular myocardium, albeit to a lesser ex‐
tent [17]. Similarly, in patients with ventricular dysfunction (a potent risk factor for atrial fi‐
brillation), various studies have also shown striking atrial structural changes [18,19].
2.2. Abnormal blood stasis
In addition to stasis consequent on the failure of atrial systole, the presence of non-valvular
atrial fibrillation seems to promote progressive left atrial (LA) dilatation [20], thus amplify‐
ing the potential for stasis. In the presence of mitral stenosis, LA dilatation is increased and
leads to further stasis and propensity to thrombosis [21]. The contribution of LA dilatation
to thrombogenesis (at least, in non-valvular atrial fibrillation) is indicated by the finding that
atrial size corrected for body surface area is an independent risk factor for stroke [22,23].
The contribution of valvular heart disease to thrombogenesis in atrial fibrillation cannot be
ignored. In mitral stenosis, up to 75% of patients with cerebral emboli on computed tomog‐
raphy or autopsy are identified to have atrial fibrillation, presumably due to alterations in
LA emptying and transmitral flow [24]. By contrast, moderate-to-severe (non-rheumatic) mi‐
tral regurgitation seems to reduce the risk of stroke with atrial fibrillation [25]. Defining pa‐
tients with atrial fibrillation and mitral valve disease who are at the greatest risk of stroke
has proved complex. The risk of emboli increases with age and in individuals with a lower
cardiac index, but seems to correlate poorly with clinical classification or mitral valve area.
Thrombogenesis in Atrial Fibrillation
http://dx.doi.org/10.5772/53613
129
Studies assessing the degree of LA dilatation have also proven inconsistent. However, an in‐
itial embolic event is highly predictive for subsequent or recurrent thromboemboli [26].
Abnormal stasis in the LA and LAA can be visualized on TEE with spontaneous echo contrast
(SEC) or pulsed-wave doppler during paroxysms of atrial fibrillation [27-30]. In sinus rhythm,
aquadriphasic pattern of blood flow can be seen in the LAA, affording minimum blood stasis
[31]. This pattern in blood flow is thought to be related to the intimate yet slightly delayed rela‐
tions between atrial and ventricular passive and active filling. In atrial fibrillation, SEC has
been shown to independently predict increased risk of thromboembolism [32].
2.3. Abnormal blood constituents
The main intravascular promoters of thrombogenesis are platelets and the various proteins of
the coagulation cascade. In atrial fibrillation, abnormal changes in both these promoters and
other blood constituents (eg, inflammatory cytokines, growth factors) are evident, thereby
completing Virchow’s triad.
2.3.1. Abnormal changes in coagulation
Abnormal haemostasis and coagulation are well described in atrial fibrillation (figure 1,ta‐
ble1). In particular, increased fibrin turnover has been reported in patients with acute onset
or chronic atrial fibrillation [33-39]. These changes initially seemed to be unrelated to the
cause of atrial fibrillation or structural heart disease [38,39]. However, abnormal concentra‐
tions of prothrombotic indices (eg, prothrombin fragments 1 and 2 and thrombin-antithrom‐
bin complexes) are more prominent in patients with stroke who have atrial fibrillation than
in those who have sinus rhythm [40], as well as in patients with atrial fibrillation and many
stroke risk factors (eg, diabetes plus heart failure) compared with either risk factor alone
[41-43]. Furthermore, some prothrombotic indices are abnormal in the patients with atrial fi‐
brillation only [44,45] and in those with paroxysmal atrial fibrillation [46]. Notably, some
markers have been proposed as suitable candidates to refine various stroke risk stratification
schema, many of which are reasonably able to identify patients at low risk or high risk of
stroke, but poor at identifying patients at moderate risk [47].
An association between various prothrombotic indices, stasis, and intracardiac thrombus
has been described [48,49]. In one study, congestive cardiac failure, a history of recent embo‐
lus, and fibrin D-dimer were shown to independently predict the presence of LAA thrombi
on TEE, leading the researchers to conclude that D-dimer could be useful in predicting the
absence of LAA thrombi [49].
The prothrombotic state also correlates with the degree of LAA dysfunction [50,51]. Further‐
more, a relation to TEE indices of stroke risk has been described. For example, SEC that is
visible during TEE shows a significant correlation to prothrombin fragments 1 and 2, fibri‐
nopeptide A, and thrombin-antithrombin III complex in non-valvular atrial fibrillation
[52,53]. Patients with atrial flutter and impaired LAA function (shown by pulsed-wave dop‐
pler) have increased amounts of of D-dimer and â -thromboglobulin[53]. In accordance with
clinical data suggesting that mitral regurgitation protects against stroke in atrial fibrillation,
a greater degree of mitral regurgitation is associated with reduced coagulation activity as es‐
timated by fibrin D-dimer amounts [54], highlighting the important contribution of stasis.
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Study design Comment
Gustafsson et al.,[55] 20 AF with stroke; 20 AF without stroke; 20 strokewithout AF; 40 healthy controls ↑D-dimer, vWF in NV AF with and without stroke
Kumagai et al., [39] 73 AF; 73 controls ↑D-dimer
Asakura et al.,[56] 83 AF vs healthy controls ↑PF1+2, TATIII
Sohara&Miyahara [57] 13 paroxysmal AF vs healthy controls NS in D-dimer, TATIII
Lip et al., [38] 87 AF; 158 controls ↑D-dimer, vWF
Lip et al., {58] 51 AF; 26 healthy controls ↑D-dimer
Kahn et al., [36]
75 NV AF with or without previous embolic events;
42 controls with or without previous thrombotic
stroke
vWF higher in AF after stroke than controls without
stroke and similar to controls after stroke
Heppell et al., [48] 109 AF with or without thrombus in left atrium ↑D-dimer, vWF, TATIII in patients with left atrialthrombus compared with patients without thrombus
Shinohara et al., [51] 45 NV AF ↑D-dimer, TATIII in patients with low LAA velocity vspatients with high LAA velocity
Feinberg (SPAF III) et al., [59] 1531 AF PF1+2 not associated with thromboembolism
Mondillo et al., [44] 45 AF; 35 healthy controls ↑D-dimer, vWF, s-thrombomodulin
Fukuchi et al., [60] AF vs without AF ↑vWF in atrial appendage tissue
Conway et al., [[61] 1321 AF ↑vWF in high-risk group for stroke
Kamath et al., [62] 93 AF; 50 healthy controls ↑D-dimer
Vene et al., [63] 113 AF ↑D-dimer in AF with cardiovascular events vs noevents
Nakamura et al., [64] LAA tissue samples of 7 NV AF vs 4 without AF ↑vWF, TF expression
Conway et al., [65] 994 AF vWF not a significant predictor of stroke and vascularevents
Kamath et al., [66] 31 acute onset AF; 93 permanent AF; 31 healthycontrols
Haematocrit raised in acute AF; ↑D-dimer in
permanent AF, but not in acute AF
Sakurai et al., [67] 28 AFL; 27 controls ↑D-dimer in patients with impaired LAA function
Inoue et al., [42] 246 NV AF; 111 healthy controls ↑D-dimer in NV AF with risk factors, NS in PF1+2
Kumagai et al., [68] 16 AF post mortem ↑vWF mRNA and protein in AF with enlargedatriums
Marin et al., [33] 24 acute onset AF; 24 chronic AF vs 24 coronaryartery disease in sinus rhythm; 24 healthy controls
↑D-dimer, vWF, s-thrombomodulin in all AF groups
with no significant after cardioversion
Nozawa et al., [69] 509 AF; 111 healthy controls ↑D-dimer, NS in PF1+2
Freestone et al., [70] 59 AF; 40 healthy controls ↑Vwf
Nozawa et al., [71] 509 NV AF ↑D-dimer but not PF1+2 with predictive significancefor thromboembolic events
Ohara et al., [43] 591 NV AF; 129 controls
↑D-dimer, PF1+2, platelet factor 4, and â-
thromboglobulin in NV AF; D-dimer, prothrombin
fragments correlated with accumulation of clinical
risk factors for stroke
AF=atrial fibrillation. NV=non-valvular. TATIII=thrombin-antithrombin III complex. AFL=atrial flutter. vWf=von Wille‐
brand factor. LAA=left atrial appendage. TF=tissue factor. NS=non-significant. PF1+2=prothrombin fragments 1 and 2.
s-thrombomodulin=soluble thrombomodulin
Table 1. Coagulation abnormal changes in atrial fibrillation [4] (with permission).
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2.3.2. Von Willebrand factor (vWf)
Further insight into the hypercoagulable state in atrial fibrillation is provided by studies of
vWf, which is a well-established index of endothelial damage and dysfunction. Raised vWf
concentrations independently predict presence of LAA thrombus in atrial fibrillation [48].
Furthermore, increased LAA endocardial expression of vWf has been described [60], espe‐
cially in those with an overloaded appendage, which seems to correlate with the presence of
adherent platelet thrombus. Furthermore, increased expression of vWf in the endocardium
has been shown to associate with enlarged LA dimensions in mitral valve disease and in‐
creased myocyte diameter [68].
Both vWf and tissue factor are overexpressed in the atrial endothelium in patients with at‐
rial fibrillation who have ahistory of cardiogenic thromboembolism—specifically in the en‐
dothelial sites containing inflammatory cells and denuded endocardium, which indicate
features of persistent myocarditis [64]. Plasma vWf and D-dimer are also positively correlat‐
ed in patients receiving either aspirin or no antithrombotic treatment, but not in those re‐
ceiving warfarin [38], further indicating the ability of warfarin to modulate the
thrombogenic process.
Furthermore, a positive association between atrial fibrillation and plasma vWf was seen in
the Rotterdam study [72]. This relation was most apparent in female patients, which could
explain the excess risk of stroke due to atrial fibrillation in women compared with men. Fur‐
thermore, plasma vWf amounts were associated with the presence of four independent risk
factors for stroke (heart failure, previous stroke, age, and diabetes) and stroke risk stratifica‐
tion schema [61,65]. Follow-up data from this study suggests that vWf concentrations might
independently predict subsequent stroke and vascular events [65,73]. However, such appli‐
cations will probably be hampered by the non-specificity of vWf, concentrations of which
are also increased in various other disorders [74,75].
2.3.3. Tissue factor
An understanding of left atrial—left atrial appendage thrombogenesis may have its roots in
distinguishing hemostatic and thrombotic clotting. Studies performed by Hoffman and
Monroe [76] offer potential mechanistic insight. In a series of wounding experiments, skin
punch biopsy tissue was placed on the dorsal skin of C57 black mice. Samples containing
the wound specimens were then collected. For comparison, thrombus was provoked in sa‐
phenous veins by application of 10% ferric chloride. After complete occlusion, tissue blocks
containing the clotted vessels were collected. Histologic evaluation revealed extensive tissue
factor staining within saphenous vein thrombi. In distinct contrast, tissue factor staining in
hemostatic clots was localized to squamous endothelial cells at the wounds edges—not
within the thrombus itself.
The experimental findings suggest that a large volume of blood must flow over an injured
surface, such as the left atrial—left atrial appendage endocardium in a person with atrial fi‐
brillation for significant tissue factor, derived from both circulating cells and microparticles
[77,78], to accumulate in high concentrations. Further, and of fundamental teleological rele‐
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vance, hemostasis occurs rapidly, with tissue factor of local origin determining the rate of
thrombus development.
The cell-based model of coagulation translates well to left atrial-left atrial appendage throm‐
bogenesis and supports
a primary role for tissue factor-based thrombin generation, with a secondary role being
played by platelets. While the results of clinical trials [79,80], and meta-analyses are consis‐
tent with this hypothesis, several biological constructs potentially provide a mechanistic
platform as well.
The integrated complexity of coagulation in general and platelet-dependent thrombin gener‐
ation in particular is becoming evident. One of the most interesting and clinically relevant
observations over the past decade is the concomitant interdependence and independence of
platelet activation and thrombin generation. The former is best considered in the context of
primary hemostasis and possibly arterial thrombosis-both highly dependent on platelet
activation, platelet aggregation and thrombin generation (in concentrations sufficient to pro‐
voke further platelet activation). In the latter instance, platelet subpopulations with distinct
intracellular calcium signaling properties yield procoagulant domains [81]. The down regu‐
lation of platelet aIIb/b3, in turn, attenuates proaggregatory potential.
2.3.4. Platelets
Many studies indicate a potential role for platelets in the hypercoagulable state (table 2).
However, the results of many of these studies have been conflicting, representing the di‐
verse aspects of platelet physiology that have been measured and possibly confounding
from interlaboratory assay variability. The available data support the notion that abnormal
changes of platelets in atrial fibrillation do exist, but the relation between these measures
and increased thrombotic risk remains uncertain, and many of such abnormal changes could
simply indicate underlying vascular comorbidities.
Choudhury and colleagues [82] recently showed that patients with atrial fibrillation had far
higher amounts of platelet microparticles and soluble P-selectin than healthy controls in si‐
nus rhythm, but no difference was seen between patients with atrial fibrillation and disease-
matched controls, implying that the abnormal changes detected were a consequence of the
underlying comorbidities rather than atrial fibrillation itself. Increased amounts of β-throm‐
boglobulin, a platelet-specific protein that indicates platelet activation and is released from
α-granules during platelet aggregation and subsequent thrombus formation, have been
shown in patients with both valvular and non-valvular atrial fibrillation compared with
controls in sinus rhythm [51,58,62,83-86]. Substantially higher β-thromboglobulin amounts
have been measured in patients with the lowest LAA flow velocities, who had greater left-
atrial dimensions [51], suggesting that platelet activation could be enhanced in patients with
a greater degree of intra-atrial stasis.
Despite the presence of enhanced platelet activation in atrial fibrillation, any firm clinical evi‐
dence indicating that it directly enhances thrombotic risk is lacking. A substudy from the
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Stroke Prevention in Atrial Fibrillation III (SPAF-III) trial [59] recorded no association between
plasma β -thromboglobulin amounts and subsequent thromboembolic events. By contrast, the
population-based Rotterdam study [87] showed that plasma concentrations of soluble P-selec‐
tin were predictive of adverse clinical outcomes in elderly patients with atrial fibrillation.
Patient group Results
Yamauchi et al., [87] 26 V AF; 73 NV AF; 57 healthy controls ↑ BTG in AF, NS in PF4
Furui et al., [95] 20 AF; 15 healthy controls BTG increase greater in AF than in controls aftertreadmill exercise
Gustafsson et al., [55] 20 AF with stroke; 20 AF without stroke; 20 strokewith sinus rhythm; 40 healthy controls ↑BTG, PF4 in NV AF with and without stroke
Sohara et al., [57] 13 paroxysmal AF vs healthy controls NS in BTG, PF4
Lip et al., [58] 51 AF; 26 healthy controls ↑BTG
Heppell [48] 109 AF with or without thrombus in left atrium ↑BTG, PF4 in patients with left atrial thrombuscompared with patients without thrombus
Minamino et al., [86] 25 AF vs healthy controls ↑mP-sel
Shinohara et al., [51] 45 NV AF ↑BTG, PF4 in patients with low LAA velocity vspatients high LAA velocity
Feinberg et al., SPAF III) [59] 1531 AF BTG not associated with thromboembolism
Minamino et al., [93] 28 AF ↑BTG, mP-sel
Mondillo et al., [44] 45 AF; 35 healthy controls ↑BTG, PF4
Kamath et al., [45] 93 AF; 50 healthy controls ↑BTG, soluble GPV; NS in platelet aggreagation
Conway et al., [61] 1321 AF sP-sel was independent of risk for stroke
Conway et al., [65] 994 AF sP-sel not a significant predictor of stroke andvascular events
Atalar et al., [96] 15 paroxysmal AF; 25 chronic AF; 22 healthycontrols
Higher BTG, PF4 in chronic AF than in paroxysmal
AF and after conversion to sinus rhythm
Nozawa et al., [69] 509 AF; 111 healthy controls ↑BTG, PF4
Sakurai et al., [53] 28 AFL; 27 controls ↑BTG in patients with impaired LAA function
Inoue et al., [42] 246 NV AF; 111 controls ↑BTG, NS in PF4
Nozawa et al., [69] 509 NV AF BTG, PF4 did not predict thromboembolic events
Choudhury et al., [97] 121 NV AF; 65 healthy controls; 78 disease-matched controls
Similar but raised levels of CD62P, CD63 and sP-sel
in AF and disease-matched controls compared with
healthy controls
Choudhury et al., [82] 70 NV AF; 46 disease controls; 33 healthy controls ↑PMP and sP-sel in AF and disease controls, but AFnot an independent determinant
Atrial fibrillation. V=valvular. NV=non-valvular. AFL=atrial flutter. BTG= β-thromboglobulin. PF4=platelet factor 4.
sPsel=soluble P-selectin. mP-sel=matrix P-selectin. GPV=glycoprotein V. LAA=left atrial appendage. NS=non-significant.
PMP=platelet microparticles.
Table 2. Studies of platelet function in atrial fibrillation [4] ( with permission)
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However, Nagao et al., [88] suggests that thromboembolism in atrial fibrillation is probably
due to enhancement of various components of the coagulation system due to stasis of blood
in the inordinate and irregular atria, rather than to platelet activation perse. The relative role
of coagulation versus platelet activation in the pathogenesis of thrombogenesis in patients
with atrial fibrillation can roughly be inferred from the results of antithrombotic drug inter‐
ventions that have been tested in randomized clinical trials [89-91]. These results indicate
that inhibition of coagulation remains the mainstay in preventing atrial fibrillation –related
thrombogenesis. The lesser but significant role of platelets- best inhibited by a combined an‐
tiplatelet drug regimen – is presumably related to the platelet activation seen in this arrhyth‐
mia could contribute to thrombogenesis indirectly. For example, increased expression of P-
selectin on platelets associated with reduced concentrations of nitric oxide has also been
shown to be a risk factor for silent cerebral infarction in patients with atrial fibrillation [92].
Moreover, raised amounts of P-selectin and CD63 have both been associated with the em‐
bolic and pre-embolic status of patients with non-rheumatic atrial fibrillation [93]. Or the
prominent involvement of platelets in the pathogenesis of atherothrombotic (that is, non-
cardiombolic) events [94].
2.3.5. Abnormal changes in fibrinolysis
Few studies have focused on fibrinolytic function in atrial fibrillation. Enhanced fibrinolysis,
shown by increased concentrations of tissue-plaminogen activator (t-PA) antigen and t-PA
inhibitor (PAI)-1 and reduced amounts of plasmin-antiplasmin complex can be attributable
to a pathophysiological response to the prothrombotic state [95,66]. However, the available
data are not consistent and conflicting results have also been reported [35]. In the Stroke Pre‐
vention in Atrial Fibrillation (SPAF) III study [99], increased concentrations of plasmin-anti‐
plasmin complexes were independently associated with thromboembolic risk factors such as
older age (>75 years), recent congestive heart failure, decreased fractional shortening, and
recent onset of atrial fibrillation. A significant correlation can be also shown between t-PA
amounts and left-atrial diameter in atrial fibrillation [35]. Predictably, anticoagulation leads
to some improvement in fibrinolytic markers in rheumatic atrial fibrillation [98].
Increased amounts of t-PA and PAI-1 can indicate the coexistence of confounders, such as
hypertension, heart failure, or ischaemic heart disease, all of which can cause endothelial
dysfunction, damage, and inflammation. However, studies in patients with atrial fibrillation
only confirm that presence of the disorder does modulate these markers. [35,95,99]. Thus,
the high amounts of t-PA and PAI-1 in atrial fibrillation could be a consequence of endothe‐
lial damage and dysfunction or represent systemic inflammation [100,101]. PAI-1 concentra‐
tions are also predictive of successful cardioversion [102], and are independent predictors of
the development of atrial fibrillation after cardiopulmonary bypass [103].
It is unclear whether increased amounts of t-PA or PAI-1 in atrial fibrillation are due to en‐
dothelial dysfunction, inflammation, fibrinolysis, or vascular disease, or a combination.
Nevertheless, abnormal changes in the fibrinolytic system might relate not only to thrombo‐
genesis but also to structural remodelling of the atria, in view of the strong links to extracel‐
lular matrix turnover.
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2.3.6. Restoration of sinus rhythm
Some evidence suggests that activation of the coagulation system could be adversely affect‐
ed by cardioversion of atrial fibrillation [104]. Electrical cardioversion has been associated
with more prominent activation of the coagulation system than a pharmacological strategy
[105]. One study found a positive correlation between the energy delivered for cardiover‐
sion to sinus rhythm and plasma D-dimer values on day 7 [105]. Additionally, an extended
duration of atrial fibrillation could lead to a more prominent hypercoagulable state (estimat‐
ed by D-dimer value) after cardioversion[106]. The hypercoagulable state after cardiover‐
sion has been seen despite optimum anticoagulation with warfarin [107]. Nevertheless,
patients receiving therapeutic low-molecular-weight heparin (LMWH) before cardioversion
seem to have reduced hypercoagulability [108].
2.4. What drives the prothrombotic state in atrial fibrillation?
Several mechanisms have been purported to drive then prothrombotic state in atrial fibrilla‐
tion (figure 2), but recent evidence has focused on the potential role of inflammation and the
release of various growth factors.
Figure 2. Abnormal changes in coagulation during atrial fibrillation [4] (with permission)
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2.4.1. Inflammation
In atrial fibrillation, inflammation might not only result in endothelial damage, dysfunction,
or activation, but also be linked directly to thrombogenesis. Increasing evidence has sup‐
ported a link between inflammation and the initiation and perpetuation of atrial fibrillation
[109-113]. Furthermore, abnormal changes in systemic inflammation have been related to
prothrombotic indices in atrial fibrillation, suggesting that inflammation could drive the
prothrombotic state in atrial fibrillation [109].
Although most cases of atrial fibrillation are associated with various comorbidities, many of
which could also enhance the baseline inflammatory state, there may be an underlying di‐
rect link between atrial fibrillation and inflammation. Interleukin-6 concentrations are ab‐
normal in atrial fibrillation, with some prognostic implications shown in one study [114].
Many studies have also shown that amounts of high-sensitivity C-reactive protein (hs-CRP)
are greater in patients with atrial fibrillation than in controls in sinus rhythm, with a step‐
wise increase in hs-CRP with the transition from patient groups with an increasing burden
(sinus rhythm to paroxysmal then persistent) in atrial fibrillation [115]. Raised hs-CRP
amounts consistently correlate with cardiovascular risk, although not with future atrial fi‐
brillation [109].More recently, high hc-CRP amounts were shown to be predictive of mortali‐
ty and vascular death in atrial fibrillation, but not stroke itself [116].
How is inflammation linked to thrombogenesis in atrial fibrillation? Both CRP and interleu‐
kin 6 stimulate tissue factor production from monocytes in vitro [117, 118]. Furthermore, in‐
terleukin 6 increases platelet production and sensitivity to thrombin [119], stimulates
transcription of fibrinogen [120], and is linked to both endothelial activation and damage
[121,122]. However, no link seems to exist between hs-CRP and thrombin-antithrombin
complexes [123]. Tissue factor and high stroke risk are also independent associates of inter‐
leukin 6, whereas fibrinogen and plasma viscosity are independent associates of hs-CRP
amounts [124].
2.4.2. Growth factors
Another potential driver for thrombogenesis could be growth factors. Various pro-angio‐
genic factors have been identified; concentrations of some of these factors have been shown
to alter in atrial fibrillation [ 70,125,126]. Vascular endothelial growth factor (VEGF) is large‐
ly produced by activated platelets [127], and results in upregulation of tissue factor mRNA
production and subsequent expression of this compound on the endothelial membrane
[128]. VEGF amounts are substantially increased in both persistent and permanent atrial fi‐
brillation, with a corresponding increase in tissue factor [125]. Additionally, raised serum
concentrations of transforming growth factor-β1[126] and angiopoetin 2 (but not angiopoe‐
tin 1) [70] are also recorded in atrial fibrillation, showing the depth and complexity of modu‐
lation of growth factor amounts.
Although the requirements for enhanced angiogenesis in atrial fibrillation are unknown, in
view of the intimate association between VEGF and tissue factor, enhanced growth factors
could be a crucial driving force behind the hypercoagulable state. Notably, tissue factor acts
Thrombogenesis in Atrial Fibrillation
http://dx.doi.org/10.5772/53613
137
as a cofactor to factor VIIa and is widely regarded as the physiological trigger to thrombin
formation [129]. But, why are factors such as the angiopoietins involved? Angiopoeitin 1
and 2 are natural co-antagonists and both compete for the same binding site on Tie-2, an en‐
dothelial tyrosine kinase receptor. With an excess of angiopoeitin 1, stability of the endothe‐
lium is favoured, whereas the converse is true with an excess of angiopoeitin 2 [70]. In these
circumstances, the balance could ultimately favour endothelial destabilisation and therefore
the action of cytokines such as VEGF.
2.4.3. Extracellular matrix turnover
The relationship between atrial fibrillation and remodeling of the left atrium/arterial ap‐
pendage is traditionally explained by the absence of contractility and altered flow dynamics.
This hypothesis is not entirely fulfilling for several reasons, not the least of which is its in‐
ability to substantiate the mechanism of progressive structural change. A contemporary
view considers the contribution of coagulation factors and thrombus substrate itself as both
initiators and perpetuators of the prothrombotic environment that includes remodeling.
Thrombin, a serine protease, beyond its widely recognized role in hemostasis and thrombo‐
sis, is directly involved in tissue repair and remodeling through an endothelial mesenchy‐
mal transdifferentiation process [130]. Thrombin also exerts an effect on endothelial cell
junctions (reviewed in [131], endothelial cell and smooth muscle cell migration and smooth
muscle cell proliferation via protease activated receptor (PAR)-1 [132].
Thrombin-induced membrane-type matrix metalloproteinase (MMP)-2 gene transcription
and activity [133] may also contribute to structural changes in the atrium/atrial appendage,
as may thrombin-augmented fibroblast-mediated collagen gel contraction [134]. Locally gen‐
erated thrombin has been shown in tissue culture to upregulate tissue factor expression and
activity [135].
While thrombin is known to possess a variety of cell regulating capabilities, one must not
overlook the contribution
of other coagulation proteases in the remodeling process. Indeed, factor Xa has been shown
to promote fibroblast proliferation, migration and differentiation into myofibroblasts
through a PAR-2 specific mechanism [136]. Accordingly, the development of oral/direct fac‐
tor Xa and thrombin inhibitors provides an unprecedented opportunity to investigate fun‐
damental pathological mechanisms in atrial fibrillation.
2.4.4. Nitric oxide
Nitric oxide is synthesized by nitric oxide synthase, which is present in large concentrations
in the endothelium. The expression of nitric oxide synthase is regulated by flow-mediated
shear stress and is consequently downregulated at sites with low flow velocity [137]. Nitric
oxide shows potent antithrombotic effects in arterial endothelium, and nitric oxide released
from activated platelets inhibits platelet recruitment to the growing thrombus [138], while
also inhibiting expression of PAI-1 [139].
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In animal models of atrial fibrillation, the loss of atrial contraction and consequent reduc‐
tion in shear stress seems to reduce LA expression of nitric oxide synthase with a corre‐
sponding decrease in nitric oxide bioavailability and increase in PAI-1 expression [140]. In
the LAA, nitric oxide concentrations were also significantly reduced compared with con‐
trol  animals,  but  this  finding did not  indicate  decreased expression of  nitric  oxide  syn‐
thase at this site. Since atrial thrombus is frequently formed in the LAA, this finding still
has no adequate explanation.
2.4.5. Renin-Angiotensin-Aldosterone System (RAAS)
The RAAS is now appreciated as key to the pathophysiology of various cardiovascular dis‐
ease states. The extent of these changes seems to relate predominantly to the reduction in
angiotensin-II amounts. Atrial tissue has the capacity to produce and use this hormone with
local expression of acetylcholinesterase and angiotensin-II receptors, both of which could be
upregulated in atrial fibrillation [141]. RAAS could be mechanistically implicated in initia‐
tion and perpetuation of atrial fibrillation [141-143], as well as providing the link to other
mechanisms promoting the prothrombotic state in atrial fibrillation.
Angiotensin II has been shown to possess several proinflammatory properties and increases
the production of proinflammatory cytokines (eg, interleukin 6 and tumour necrosis factorα
[TNFα]), adhesion molecules (eg, vascular-cell adhesion molecule 1), monocyte chemoat‐
tractant protein 1, and selectins (eg, P-selectin) [144-146]. Similarly, through release of vari‐
ous chemokines (eg, cytokine-induced neutrophil chemoattractant), angiotensin II can
initiate neutrophil recruitment [146]. Expression of angiotensin-II receptors has also been
linked with increased atrial cell death and leucocyte infiltration [147]. These data potentially
support a complex relation between RAAS, inflammation, and atrial fibrillation.
Additionally, RAAS has been implicated in the activation of various MMPs and thromboxane
A2 (a prothrombotic signalling molecule produced by activated platelets). These processes
could occur both as a direct effect of angiotensin II and also through induction of interleukin 6
[148]. Furthermore, angiotensin II could accelerate degradation of nitric oxide through produc‐
tion of reactive oxygen species and thereby impair endothelium dependent vasodilatation
[149]. Likewise, activation of RAAS increases synthesis of PAI-1, possibly indicating either en‐
hanced endothelial damage or impaired fibrinolysis in atrial fibrillation [150].
3. Conclusion
The mechanisms underlying thrombogenesis in atrial fibrillation are clearly complex and re‐
main only partly understood. Abnormal changes in flow, vessel wall, and blood constituents in
atrial fibrillation fulfil Virchow’s triad for thrombogenesis, and accord with a prothrombotic or
hypercoagulable state in this arrhythmia. That this process is related purely to blood stasis is no
longer accepted. Various abnormal changes related both to atrial fibrillation and its comorbidi‐
ties impart a synergistic effect in maintaining a hypercoagulable state in this condition.
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